CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
LY3074828biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03456713
NCT03456713Phase 1Completed

A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects

Eli Lilly and Company·interventional·Posted Mar 7, 2018·Updated Feb 20, 2024

In Brief

A Phase 1 clinical trial evaluating LY3074828 for Healthy. Completed, enrolled 72 participants across 1 site.

Detailed Summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828, when given as a solution formulation in different devices. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 7, 2018
Enrollment StartMar 6, 2018
Primary CompletionAug 13, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.3 years ago

Interventions

LY3074828biological

Administered SC